论文部分内容阅读
目的:分析在常规乙型肝炎治疗基础上加用谷胱甘肽含片对慢性乙型肝炎近期与远期的临床疗效。方法:将120例慢性乙型肝炎患者随机化分为观察组和对照组,每组60例。对照组给予拉米夫定片联合阿德福韦酯片口服治疗,观察组在对照组治疗基础上加用谷胱甘肽含片口服治疗,两组连续治疗3个月后观察对比两组患者血清乙肝病毒的脱氧核糖核酸(HBV-DNA)水平、乙型肝炎E抗原血清转换率、乙肝表面抗原血清转换率、丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)和总胆红素(TBIL)以及安全性指标等。结果:两组患者治疗3、6、9、12个月的血清HBV-DNA水平均呈逐渐下降趋势,组内比较差异有统计学意义(P<0.05),观察组治疗3、6、9、12个月后的血清HBV-DNA水平均较对照组显著降低(P<0.05);两组治疗3、6、9、12个月后的ALT、AST和TBIL指标均呈下降趋势(P<0.05),且组间比较观察组较对照组显著降低(P<0.05);两组随访12个月HBV-DNA、乙型肝炎E抗原、乙肝表面抗原阴转率比较,观察组均优于对照组,均P<0.01,差异有统计学意义;两组均未见谷胱甘肽含片药物相关不良反应。结论:慢性乙肝患者治疗中加用谷胱甘肽含片辅助治疗能够更好地控制患者病情,并且副作用小。
Objective: To analyze the clinical efficacy of glutathione tablets in the treatment of chronic hepatitis B in the short and long term based on the conventional treatment of hepatitis B. Methods: 120 patients with chronic hepatitis B were randomly divided into observation group and control group, 60 cases in each group. The control group was given lamivudine tablets combined with adefovir dipivoxil tablets orally, the observation group was treated with glutathione buccal tablets on the basis of the control group. After two months of continuous treatment, the patients in two groups were observed and compared Serum hepatitis B virus DNA (HBV-DNA) levels, hepatitis B E antigen seroconversion rate, hepatitis B surface antigen seroconversion rate, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total Bilirubin (TBIL) and safety indicators. Results: The levels of serum HBV-DNA decreased gradually at 3, 6, 9 and 12 months after treatment in both groups, the difference was statistically significant (P <0.05) The levels of serum HBV-DNA in 12 months after treatment were significantly lower than those in control group (P <0.05). The ALT, AST and TBIL indexes in both groups decreased after 3, 6, 9 and 12 months ), And compared between the two groups were significantly lower than the control group (P <0.05); 12 months after the two groups were followed up HBV-DNA, hepatitis B E antigen, hepatitis B surface antigen negative conversion rate, the observation group were better than the control group , Both P <0.01, the difference was statistically significant; glutathione tablets drug-related adverse reactions were not seen in both groups. Conclusion: The treatment of chronic hepatitis B with glutathione tablets adjuvant therapy can better control the patient’s condition, and the side effects.